Insomniatherapeutics Market By Drug Class (Nonbenzodiazepines, Benzodiazepines andOthers) and By Distribution Channel (Retail & Hospital Pharmacies andOnline Pharmacies) - Global Industry Insights, Trends, Outlook, and OpportunityAnalysis, 2018-2026
Insomnia is a common type ofsleep disorder and frequently co-morbid with mental or psychiatric illness.Consistent risk factors for insomnia are age, and stress associated with job,family, financial, and medical conditions. Increase in consumption of alcohol,caffeine, nicotine could also lead to insomnia. Depending on the duration,insomnia is categorized into transient and chronic insomnia. Transient insomnialast for a single night to few weeks or months and is an adaptive response tothe above mentioned challenges. Chronic insomnia is more complex resulting fromcombination of factors mentioned above and lasts for longer period of time.Insomnia is normally treated with prescription medication or over the countersleep aid such as natrol melatonin and unisom sleep gel help people to fallasleep with minimum side effects. According to a study by University of Laval,2011, about 40 % of the adult Canadian are experiencing one or more symptoms ofinsomnia. Further, a latest research reported in Nature, 2017, stated thatinsomnia increases the risk in women to deliver premature babies by 30%.Increase in incidence of insomnia across the globe will propel the insomniatherapeutics market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/958
New improved medication withlesser side effects will drive the insomnia therapeutics market growth globally
Benzodiazepines (BZP) such astemazepam and diazepam are the commonly prescribed medication for insomnia.Though these medications are effective, prolonged use of these drugs may causecognitive impairment, dependency and addiction. The launch of novel drugs suchas Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7countries in the insomnia therapeutics and is expected market over the forecastperiod.
Intermezzo (2014), are used insmall doses and administered under the tongue for faster absorption. Tesimeltonapproved by FDA in 2014 is the only drug approved by FDA for Non-24-HourSleep-Wake Rhythm Disorder and it lacks abuse potential. These products areexpected to drive the insomnia therapeutics market over the forecast period.
Increasing awareness andtreatment seeking rates for insomnia are expected to further contribute to thegrowth of the market. However, the loss of exclusivity of the drugs led themarket more genericized, creating a competitive environment for new entrants.For instance, non-benzodiazepines and low dose sedating anti-depressants, stillconsidered as a first line of medication for the insomnia, are facing stiffcompetition from the generics.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/insomnia-therapeutics-market-958
According to a report by SleepResearch Society, 2012, 20% of the general adult population in Canada and U.Sis suffering from insomnia and this number is expected to increase in the nearfuture. Problems like daytime sleepiness, and fatigue is affecting largernumber of population and imposing a considerable burden on these regions. Thesefactors all together will trigger the total insomnia therapeutics market demandin the future period.
Devices would have a negativeimpact on the global insomnia therapeutics market
Rapid entry of new players andnew devices for insomnia will boost the market over the forecast period. FDAapproved new device Cerêve Sleep System for insomnia in 2016 this device isused to reduce latency to stage 1 and stage 2 sleep by keeping the foreheadcool. Major players in insomnia therapeutics market are GlaxoSmithKline plc,UCB Group, Otsuka Holdings Co., Ligand Pharmaceuticals Incorporated, AxxonisPharma AG, Kyowa Hakko Kirin Co. Ltd., National Institute of NeurologicalDisorders and Stroke, Jazz Pharmaceuticals, Inc. Ltd., Omeros Corporation andManhattan Pharmaceuticals, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/958
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
